Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Health and Quality of Life Outcomes May 8, 2023 Carol Jamieson, Vanina Popova, Ella Daly et al. 18 citations
Patients with treatment-resistant depression who received esketamine nasal spray plus an oral antidepressant reported greater improvements in health-related quality of life and daily functioning after 28 days compared to those who received a placebo nasal spray plus an antidepressant. At day 28, a lower percentage of patients in the esketamine group reported problems across all five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The esketamine group also showed larger average improvements in health status index and overall health rating, as well as greater reductions in functional disability.